

Table (Continued)

Principal Characteristics of Patients Diagnosed With Coronary Artery Disease Who Answered the MEDAS-14 Screener

<i>Duration of CAD</i>	
0-2 years	40 (36)
3-5 years	40 (36)
6-12 years	20 (18)
12 or more years	10 (9)
<i>Seen in hospital in the past 12 months by</i>	
Cardiologist	53 (48)
Cardiology nurse	8 (7)
Cardiology accident and emergency services	11 (10)
Admitted to cardiology	9 (8)
<i>Treated with cardioprotective drugs</i>	
Statins	104 (95)
ACE-inhibitors or ARA-II	78 (71)
Beta-blockers	80 (73)
Antiplatelet agents	105 (95)
<i>MEDAS-14, mean (SD), score</i>	
< 9 points	41 (37)
≥ 9 points	69 (63)

ACE-inhibitors, angiotensin converting enzyme inhibitors; ACS, acute coronary syndrome; ARA-II, angiotensin II receptor antagonist; CAD, coronary artery disease; CVRF, cardiovascular risk factors; MEDAS-14, 14-point mediterranean diet adherence screener.

* Some patients suffered angina and ACS.
The values express No. (%) or mean (standard deviation).

MedD, as key elements for the superior efficacy of this diet compared with a low-fat diet.

It is likely that the MedD will be clearly reinforced as an intervention to be included in nonpharmacological treatment for preventing cardiovascular disease,⁶ thanks to the possibility of new studies backing the results published by de Lorgeril et al.³

The data from this study show that a majority of patients with CAD (63%) had acceptable adherence to the MedD. The application of the MEDAS-14 screener makes it possible to identify which aspects require improvement and provides the opportunity to focus and adapt a dietary intervention.

Acknowledgements

Pere Roura Poch, biostatistician at the Unitat de Suport a la Recerca de la Gerencia Territorial de la Catalunya Central, for his cooperation and comments.

Joan Tobias Ferrer,^{a,*} Immaculada Santasusana Riera,^b Mireia Cuadrench Solórzano,^a Miquel Gonzalez Cabré,^a Montserrat Girbau Tapias,^b and Cristina Sant Masoliver^b

^aMedicina Familiar y Comunitaria, Equipo de Atención Primaria Plaça Catalunya, Centro de Atención Primaria Bages (CAP Bages), Gerència Territorial Catalunya Central, Institut Català de la Salut, Departament de Salut, Generalitat de Catalunya, Manresa, Barcelona, Spain

^bEnfermeria, Equipo de Atención Primaria Plaça Catalunya, Centro de Atención Primaria Bages (CAP Bages), Gerència Territorial Catalunya Central, Institut Català de la Salut, Departament de Salut, Generalitat de Catalunya, Manresa, Barcelona, Spain

* Corresponding author:

E-mail address: jtobiasf.cc.ics@gencat.cat (J. Tobias Ferrer).

Available online 4 December 2014

REFERENCES

1. Estruch R, Ros E, Salas-Salvadó J, Covas MI, Corella D, Arós F, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. *N Engl J Med*. 2013;368:1279–90.
2. Schröder H, Fitó M, Estruch R, Martínez-González MA, Corella D, Salas-Salvadó J, et al. A short screener is valid for assessing Mediterranean diet adherence among older Spanish men and women. *J Nutr*. 2011;141:1140–5.
3. De Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. *Circulation*. 1999;99:779–85.
4. Lopez-Garcia E, Rodriguez-Artalejo F, Li TY, Fung TT, Li S, Willett WC, et al. The Mediterranean-style dietary pattern and mortality among men and women with cardiovascular disease. *Am J Clin Nutr*. 2014;99:172–80.
5. Muñoz M, Guallar P, Graciani A, López E, Mesas AE, Aguilera MT, et al. Adherence to the Mediterranean diet pattern has declined in Spanish adults. *J Nutr*. 2012;142:1843–50.
6. Arós F, Estruch R. Dieta mediterránea y prevención de la enfermedad cardiovascular. *Rev Esp Cardiol*. 2013;66:771–4.

<http://dx.doi.org/10.1016/j.rec.2014.07.023>

Theoretical Impact on Coronary Disease of Using a Computerized Clinical Decision Support System in the Prescription of Lipid-lowering Treatment



Impacto teórico en la enfermedad coronaria de usar un sistema informatizado de ayuda en la prescripción del tratamiento hipolipemiante

To the Editor,

Low-density lipoprotein cholesterol (LDL-C) is a strong cardiovascular risk factor, especially for coronary artery disease.¹ However, in Spain, there is plenty of room for improvement in increasing the number of patients at very high cardiovascular risk who attain lipid goals.^{1,2} Recently, our group published the results of the first validation study of the computerized European clinical decision support system (CDSS) specific to lipid-lowering therapy (designated in Spanish as HTE-DLP).³ The study shows that the number of patients who reach the treatment goal of LDL-C < 70 mg/dL increases 4.4 times with use of the HTE-DLP by experts

in vascular risk.³ The objective of the present study was to assess the theoretical impact on the frequency of coronary artery disease of using the HTE-DLP throughout Spain with the CASSANDRA-REGICOR methodology.⁴

The CASSANDRA-REGICOR system permits an estimate of the number of fatal and nonfatal coronary events that would occur in the Spanish population in the next 10 years in different scenarios according to trends in prevalence of cardiovascular risk factors. The system uses incidence data on coronary disease and risk factor prevalence from the REGICOR study. Extrapolation to Spain is based on data from the IBERICA study (incidence) and the DARIOS study (risk factor prevalence). The number of coronary events was predicted for 2010 to 2020 in patients aged between 35 and 75 years old. Population projections were provided by the Catalan Statistics Institute (IDESCAT) and Spanish National Statistics Institute (INE). The application enables an assessment of the impact of different scenarios of risk factor prevalence.⁴

The HTE-DLP is the first CDSS for lipid-lowering treatment developed in Spain (RTA98/09) (Figure). It is based on the 2011 European guidelines for lipid-lowering treatment. Taking

HTEdislipemia - Búsqueda de Tratamientos Hipolipemiantes

Datos del Paciente Encuesta Tratamientos Encontrados Especialidades para tratamiento con Atorvastatina 80 mg. + Ezetimiba 10 mg.

1. Nivel inicial C-LDL

Indicar nivel de C-LDL obtenido en analítica (mg/dl):

Bajo tratamiento con estatinas (estimar C-LDL inicial)

2. Objetivo terapéutico (nivel C-LDL)

Usar asistenteo seleccionar un perfil de riesgo:

Riesgo muy alto ?

(ECV documentada ó DM con LOD ó FGR < 60 ml/min/1,73m², ó SCORE > 10%)

5. Buscar tratamientos

Mostrar los 5 mejores tratamientos viables y efectivos

Buscar Limpiar Imprimir Unidades

Encontrados 2 tratamientos - Se muestran 2

3. Datos Complementarios

Paciente varón

C.HDL (mg/dl):

Activar Estadística

Otras situaciones:

Insuficiencia Renal (FGR < 30)

Insuficiencia Hepática (Chilφ = B)

4. Tratamientos concomitantes

Acenocumarol

Acido Fusídico

Acido acetil-salicílico

Aliskiren

Amiodarona

Amoldipino

Antirretrovirales: Telaprevir

Antirretrovirales: Abacavir

Antirretrovirales: Amprenavir

Antirretrovirales: Atazanavir

Antirretrovirales: Boceprevir

Antirretrovirales: Darunavir

Antirretrovirales: Delavirdina

Antirretrovirales: Didanosina

Antirretrovirales: Efavirenz

Antirretrovirales: Efavirenz

Antirretrovirales: Emtricitabina

Antirretrovirales: Estavudina

Antirretrovirales: Etravirina

Antirretrovirales: Fosamprenavir

Antirretrovirales: Indinavir

ATENCIÓN:

Por favor, indique el tratamiento hipolipemiante actual del paciente para calcular el nivel C-LDL original. Si pulsa en cancelar está señalando que el paciente toma tratamiento hipolipemiante pero que desconoce cual es. En este caso se aplicará un 30% de incremento sobre el valor actual de C-LDL:

NOTA: Recuerde que existe una variabilidad individual en la respuesta a la acción de las estatinas. En pacientes hipo-respondedores bajo tratamiento con estatinas puede suceder que a pesar de no estar en objetivos el programa ofrezca como primera opción el tratamiento que está tomando en la actualidad. En estos casos elija la 2ª opción ofrecida.

- Atorvastatina 10 mg.
- Atorvastatina 10 mg. + Ezetimiba 10 mg.
- Atorvastatina 20 mg.
- Atorvastatina 20 mg. + Ezetimiba 10 mg.
- Atorvastatina 40 mg.
- Atorvastatina 40 mg. + Ezetimiba 10 mg.
- Atorvastatina 80 mg.
- Atorvastatina 80 mg. + Ezetimiba 10 mg.
- Fluvastatina 20 mg.
- Fluvastatina 20 mg. + Ezetimiba 10 mg.

Aceptar Cancelar

HTEdislipemia - Búsqueda de Tratamientos Hipolipemiantes

Datos del Paciente Encuesta Consultar (desde Internet) ficha de la AEMPS para ATORVASTATINA NORMON EFG 80 mg. Consultar (desde Internet) ficha de la AEMPS para EZETROL 10 mg. Ezetimiba 10 mg.

Opciones para el tratamiento con Atorvastatina 80 mg. + Ezetimiba 10 mg.

(C-LDL esperado: 38 - 65) (C-HDL esperado: N.D.) (C-LDL/C-HDL esperado: N.D.) (Disminución RCV esperada: 65%)
(Son aplicables las advertencias 01,02,03,04,05,06, además de las generales)

Orden	Especialidad(es) Farmacéutica(s)	P.V.P.	Diferencia PVP Mínimo
	ATORVASTATINA NORMON EFG 80 mg. + EZETROL 10 mg.	88,25 €	0 €
	ATORVASTATINA PENZA EFG 80 mg. + ABSORCOL 10 mg.	88,25 €	0 €
	ATORVASTATINA PENZA EFG 80 mg. + EZETROL 10 mg.	88,25 €	0 €
	ATORVASTATINA PHARMACIA EFG 80 mg. + ABSORCOL 10 mg.	88,25 €	0 €
	ATORVASTATINA PHARMACIA EFG 80 mg. + EZETROL 10 mg.	88,25 €	0 €
	ATORVASTATINA QUALIGEN EFG 80 mg. + ABSORCOL 10 mg.	88,25 €	0 €
	ATORVASTATINA QUALIGEN EFG 80 mg. + EZETROL 10 mg.	88,25 €	0 €
	ATORVASTATINA RATIO EFG 80 mg. + ABSORCOL 10 mg.	88,25 €	0 €
	ATORVASTATINA RATIO EFG 80 mg. + EZETROL 10 mg.	88,25 €	0 €
	ATORVASTATINA RATIOPHARM EFG 80 mg. + ABSORCOL 10 mg.	88,25 €	0 €
	ATORVASTATINA RATIOPHARM EFG 80 mg. + EZETROL 10 mg.	88,25 €	0 €
	ATORVASTATINA SANDOZ EFG 80 mg. + ABSORCOL 10 mg.	88,25 €	0 €
	ATORVASTATINA SANDOZ EFG 80 mg. + EZETROL 10 mg.	88,25 €	0 €
	ATORVASTATINA STADA GENERICOS EFG 80 mg. + ABSORCOL 10 mg.	88,25 €	0 €
	ATORVASTATINA STADA GENERICOS EFG 80 mg. + EZETROL 10 mg.	88,25 €	0 €
	ATORVASTATINA TARBIS EFG 80 mg. + ABSORCOL 10 mg.	88,25 €	0 €

Mensajes y Advertencias

- Precauciones a seguir para la prevención de la miopatía en la terapia de combinación con estatinas y fibratos: verificar función renal y tiroidea previo al inicio, administrar las estatinas 12 horas separadas de los fibratos, evitar otros fármacos con posibles interacciones, usar dosis bajas- medias de estatina al inicio, usar preferentemente fenofibrato o bezafibrato (el uso de gemfibrozilo está contraindicado), instruir al paciente sobre los síntomas de miopatía y controlar los niveles de creatinina si síntomas musculares
- Recuerde que el riesgo de miopatía con el uso de tratamiento hipolipemiante está aumentado en pacientes: mayores de 70 años, con insuficiencia renal, hipotiroidismo no controlado, antecedentes personales o familiares de trastornos musculares hereditarios, historia previa de toxicidad muscular con una estatina o fibrato, alcoholismo, enfermedad multisistémica, toma concomitante de otros fármacos (fibratos, sobre todo gemfibrozilo, ciclosporina, antifúngicos, azoles, itraconazol, ketoconazol, macrólidos, eritromicina, claritromicina, inhibidores de la proteasa del VIH, nefazodona, amiodarona), pacientes polimedicados y períodos perioperatorios
- Una vez el paciente se encuentre en objetivos lipídicos valorar realizar un control lipídico cada 6 meses si es de alto riesgo vascular, a los 6-12 meses si es de riesgo intermedio (recalculando el riesgo en cada ocasión) y bianualmente en los de bajo riesgo

ADVERTENCIAS PROPIAS DE [Atorvastatina 80 mg. + Ezetimiba 10 mg.]:
(Leyenda: advertencia grave - advertencia moderada - advertencia leve - advertencia informativa)

- (01) - Si la propuesta de tratamiento es atorvastatina (80 mg) se recomienda iniciar tratamiento con 40 mg. Realizar un control analítico a las 6 semanas y reevaluar el tratamiento. Si el descenso de C-LDL necesario para alcanzar objetivos es superior al 6% (equivalente a doblar dosis) posiblemente se trate de un paciente hipo-respondedor a estatinas. En los pacientes hipo-respondedores se recomienda elegir una opción de tratamiento hipolipemiante que incluya terapia de combinación (estatina+ezetimibe)
- (02) - El uso concomitante de atorvastatina y cantidades importantes de alguna de las siguientes sustancias (cimicifuga racemosa, hierba de San Juan (hipérico), pectina, salvado de avena) puede dar lugar a interacciones farmacológicas mayores o graves.
- (03) - El uso de terapia combinada (estatina y ezetimibe o ácido nicotínico) aumenta el riesgo de miopatía
- (04) - Los efectos adversos más frecuentes de la atorvastatina son: dolor abdominal, estreñimiento, flato, indigestión, aumento moderado de enzimas hepáticas y dolor de cabeza
- (05) - Los efectos adversos más frecuentes de la ezetimibe son: diarrea, artralgias, mialgias, nasofaringitis, sinusitis e infecciones del tracto respiratorio superior
- (06) - Si no se alcanzan objetivos terapéuticos con estatinas en combinación con ezetimiba se puede valorar terapia triple (añadiendo secuestradores de ácidos biliares o ácido nicotínico / laropiprant)(recomendación IIb, nivel de evidencia C).

Figura. Ejemplo de la interfaz del sistema informatizado de ayuda en la toma de decisiones del tratamiento hipolipemiante (HTE-DLP).

Table

Effect of Using HTE-DLP on the Incidence Rate and Number of Fatal and Nonfatal Coronary Events in Individuals Aged 35 to 74 Years and Health Expenditure Extrapolated to 2020 According to Estimates Based on the CASSANDRA-REGICOR System

	Control	Use of HTE-DLP
Estimated male population	12 502 843	
Estimated female population	12 951 521	
Incidence rate/100 000 men	234.5-238.4	220.5-220.7
Incidence rate/100 000 women	50.3-50.5	49.4-49.5
Number of expected cases of coronary artery disease in men	29 139-29 807	27 569-27 594
Number of expected cases of coronary artery disease in women	6515-6541	6398-6411
Estimated cost of coronary artery disease in men, millions of Euros	409 956 591 419 354 683	387 868 261 388 219 986
Estimated cost of coronary artery disease in women, millions of Euros	91 659 535 92 035 329	90 013 462 90 196 359
Number of coronary events avoided in men		1570-2213
Number of coronary events avoided in women		117-130
Reduction in costs due to coronary events avoided in men, millions of Euros		22 088 330 30 815 343
Reduction in costs due to coronary events avoided in women, millions of Euros		1 646 073 1 838 970

HTE-DLP, computerized clinical decision support system for lipid-lowering treatment. Values presented with upper and lower 95% CI for the mean total cholesterol.

into account patients' cardiovascular risk, comorbidities, and concomitant drugs, the application presents all lipid-lowering therapeutic options for a specific patient, ordered from best to worst according to criteria of efficacy, safety, and cost-effectiveness.³

The mean (SD) value of total cholesterol in HTE-DLP users after 12 weeks was 156.6 (44) mg/dL,³ which in the CASSANDRA-REGICOR system would be equivalent to the effect of the theoretical maximum reduction of 23% for men and 24% for women. To calculate the effect of health costs, a mean cost per coronary event of 14 069 Euros was applied; 87% of this sum corresponds to direct costs and 13% to loss of productivity.⁵

Use of the HTE-DLP throughout Spain in 2020 would lead to a decrease in fatal and nonfatal coronary events in individuals aged 35 to 74 years of between 5.4% and 7.4% in men and 1.8% and 2.0% in women. This would correspond to a decrease in health costs for coronary disease of between 4.7% and 6.4% (Table).

Of the studies published to date on CDSS for lipid-lowering treatment, only the study by Gilutz et al⁶ in 7448 patients has found a decrease (2.1% in this case), in the number of readmissions to hospital per year for coronary artery disease in the intervention group.

The use of CDSS for lipid-lowering treatment may have an impact not only on direct costs of lipid-lowering medication, which were 19% lower in the case of HTE-DLP for every 1 mg decrease in LDL-C,³ but also on indirect costs of these events.

The limitations of the study include the fact that the estimates are approximations to reality based on clinical practice, risk factor prevalence, degree of control, and current demographic trends. In the future, this figure may turn out to be an underestimate, particularly for women, in view of possible variations in the prevalence of risk factors, such as increased prevalence of obesity, hypertension, and diabetes mellitus, and a greater than expected survival of the population, with more individuals aged 75 years or greater. On the other hand, the availability of new drugs and improvements in clinical practice may increase the number of patients who attain their treatment goals, and the findings may be

an overestimate. Finally, we should bear in mind that the study data have been extrapolated from the HTE-DLP validation study in a small sample. It is important to highlight that the data used were subject to quality control to guarantee their internal and external validity. However, large prospective studies would be needed in real clinical practice to measure the true effect and safety of CDSS.

In conclusion, the general use in clinical practice of a computerized system for supporting prescription of lipid-lowering treatment may have a positive impact on coronary artery disease and help to optimize the use of health resources.

FUNDING

The present study was partly funded with a grant from the Instituto de Salud Carlos III to the Cardiovascular Research Network (*Red de Investigación Cardiovascular*) (Heracles Program, RD12/0042) and AGAUR (2014 SGR 240).

CONFLICTS OF INTEREST

A. Zamora and F. Fernández de Bobadilla have intellectual property protection for HTE-DLP.

Alberto Zamora,^{a,b,*} Carme Carrion,^b Gabriel Vázquez-Oliva,^c Guillem Paluzie,^a Anabel Martín-Urda,^d and Roberto Elosua^e

^aUnidad de Riesgo Vascular, Hospital de Blanes, Corporació de Salut del Maresme i la Selva, Blanes, Girona, Spain

^bTransLab Research Group, Grupo de Medicina Translacional y Ciencias de la Decisión, Facultad de Medicina, Universidad de Girona, Girona, Spain

^cServicio de Cardiología, Hospital Universitario Dr. Josep Trueta, Girona, Spain

^dServicio de Medicina Interna, Serveis de Salut Integrats del Baix Empordà, Hospital de Palamós, Palamós, Girona, Spain

^eEpidemiología y Genética Cardiovascular, IMIM (Instituto Hospital del Mar de Investigaciones Médicas), Barcelona, Spain

* Corresponding author:

E-mail address: azamorac.zamora@gmail.com (A. Zamora).

Available online 4 December 2014

REFERENCES

1. Pérez de Isla L, Saltijeral Cerezo A, Vitale G, González Timón B, Torres do Rego A, Alvarez-Sala Walther LA. Cifras de colesterol adecuadas en pacientes coronarios y diabéticos. Análisis según especialidades médicas y comunidades autónomas. Rev Esp Cardiol. 2013;66:748-9.

- Cordero A, López-Palop R, Bertomeu-González V, Carrillo P, Moreno-Arribas J, Bertomeu-Martínez V. Perfil clínico y pronóstico de los pacientes con síndrome coronario agudo y colesterol unido a lipoproteínas de baja densidad < 70 mg/dl. Rev Esp Cardiol. 2013;66:588-9.
- Zamora A, Fernández de Bobadilla F, Carrion C, Vázquez G, Paluzie G, Elosua R, et al.; VALIDA Study Group; Network of Lipid Units of Catalonia (XULA). Pilot study to validate a computer-based clinical decision support system for dyslipidemia treatment (HTE-DLP). Atherosclerosis. 2013;231:401-4.
- Grau M, Subirana I, Vila J, Elosua R, Ramos R, Sala J, et al. Validation of a population coronary disease predictive system: the CASSANDRA model. J Epidemiol Community Health. 2014 Mar 11. <http://dx.doi.org/10.1136/jech-2013-203516>.
- Fernández de Bobadilla F, López de Sá E. Carga económica y social de la enfermedad coronaria. Rev Esp Cardiol Supl. 2013;13:42-7.
- Gilutz H, Novack L, Shvartzman P, Zelingher J, Bonne DY, Henkin Y, et al. Computerized community cholesterol control (4 C): meeting the challenge of secondary prevention. Isr Med Assoc J. 2009;11:23-9.

<http://dx.doi.org/10.1016/j.rec.2014.08.006>

Predicting the Risk of Systemic Septic Embolism in Patients With Infective Endocarditis



Predicción del riesgo de embolia sistémica séptica en pacientes con endocarditis infecciosa

To the Editor,

Despite the progress made over the past decades in the management of infective endocarditis, the mortality rate is still high.¹ Embolic events (EE) are the most frequent extracardiac complication, with an incidence of symptomatic EE ranging from 10% to 50%,² affecting mainly the central nervous system and therefore worsening prognosis.³

The possibility of EEs also affects treatment options, as surgery is indicated to prevent them; a recent study showed that early surgery significantly reduces EE occurrence.⁴ As they are early-onset phenomena in infective endocarditis, it is essential to quantify the embolic risk at the time of diagnosis in order to avoid this complication and help in the therapeutic decision-making process.

Two systems for predicting embolic risk in infective endocarditis were designed recently, one French⁵ and one Italian⁶. Our objective was to test and compare the clinical utility of both systems.

We studied 153 consecutive patients admitted to a tertiary care center between January 2009 and April 2014 with a diagnosis of infective endocarditis according to the modified Duke criteria. In the first 24 hours of admission, all patients underwent a transthoracic echocardiogram and 90% took a transesophageal one.

The embolic risk was calculated using the French system, which gives 1 point to each of the following covariates: diabetes mellitus, atrial fibrillation, vegetation > 10 mm, embolism prior to antibiotic therapy and *Staphylococcus aureus*. Age was added as a continuous variable to the sum of the above points, as per the French system, to estimate EE risk.⁵ The risk was also calculated using the Italian system, assigning 1 point to vegetation ≥ 13 mm and 1 point to *S. aureus*. Patients were classified as being at high risk of embolism if they had a probability > 7.5% according to the French system and of 2 points using the Italian system.

The performance of both systems in predicting EEs based on diagnosis and having started antibiotic therapy was evaluated using

a Cox regression model. Embolic events based only on clinical suspicion or cutaneous manifestations were not considered.

The clinical, echocardiographic, and microbiological data are shown in the Table. The Charlson comorbidity index was 4 (SD,2). The length of the vegetation was 8 (SD,7) mm on the transthoracic and 10 (SD,7) mm on the transesophageal echocardiogram. While in hospital, 27 (17.6%) EEs were recorded, 16 (59.9%) affecting the central nervous system. In-hospital mortality was 3 times higher (12/27; 44.4%) in patients with EE than in patients without EE (11.9%).

The estimations generated with the French system showed a significant association with embolic risk (hazard ratio [HR] = 2.7; 95% confidence interval [95%CI], 1.37-5.46). However, of the 27 patients who suffered an EE, 12 (44.4%) had been classified as low risk. The occurrence of EE was better predicted by this system than by chance ($P = .03$), although its discrimination was moderate (C-statistic = 0.66; 95%CI, 0.54-0.77).

The estimations from the Italian model were also associated with embolic risk: HR = 2.2 (95%CI, 1.28-3.92) and C = 0.62 (95%CI, 0.49-0.74; $P = .05$). In this model, 85.2% (n = 23) of patients who suffered an EE had been classified as low risk.

Calibration of both models was adequate ($P \geq .2$). Compared with the Italian system, the French one showed a net reclassification improvement index of 7.4% ($P = .5$).

Therefore, although both models have a similar predictive power, the French system better classifies patients who are at low embolic risk than the Italian one. The main advantage of the Italian system is that it is easier to use, requiring only two variables, whereas the French system, apart from using a greater number of variables, requires software for its calculation.⁵ In our cohort, only 1 patient had a right-sided embolism. Excluding her from the analysis did not affect the general results; therefore, in essence our results refer to left-sided embolisms.

In conclusion, in this contemporaneous series of infective endocarditis, approximately 1 in 6 patients had EE after their diagnosis or start of antibiotic therapy. The unadjusted excess risk of in-hospital death of patients with EE is around 30%. It is possible to predict the embolic risk with a simple clinical tool. In our population, the French system was shown to be more useful; therefore, including it as part of the clinical judgement should help to improve the therapeutic decision-making process, making it